NDC 43742-2359-1 HUMAN OTC DRUG

Drug Status:  Active

Proprietary Name: Female Stimulant

Drug Overview

The NDC Code 43742-2359-1 is assigned to “Female Stimulant ” (also known as: “Aconiticum Acidum, Cis-, Apis Venenum Purum, Aquilegia Vulgaris, Bovista, Cypripedium Pubescens, Estradiol, Faecalis (alkaligenes), Folliculinum, Funiculus Umbilicalis Suis, Glandula Suprarenalis Suis, Heart (suis), Hydrastis Canadensis, Hypophysis Suis, Kreosotum, Lachesis Mutus, Lilium Tigrinum, Magnesia Phosphorica, Mercurius Solubilis, Mutabile Bacillus (bach), Oophorinum (suis), Petroselinum Sativum, Pineal Gland (suis), Placenta Totalis Suis, Progesterone, Sepia, Testosterone, Uterus (suis)”), a human otc drug labeled by “Deseret Biologicals, Inc.”. The product's dosage form is liquid, and is administered via oral form.

Disclaimer

Do not rely on DataLabs to make decisions regarding medical care. Always speak to your health provider about the risks and benefits of FDA-regulated products. We may limit or otherwise restrict your access to the API/WEB in line with our Terms of Service.

Drug Information
NDC Package Code	43742-2359-1
	The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC.
Product NDC	43742-2359
	The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
11 Digit NDC Code	43742-2359-01
	It should be noted that many NDCs are displayed on drug packaging in a 10-digit format. Proper billing of an NDC requires an 11-digit number in a 5-4-2 format. Converting NDCs from a 10-digit to 11-digit format requires a strategically placed zero, dependent upon the 10-digit format.
Proprietary Name	Female Stimulant
	Also known as the trade name. It is the name of the product chosen by the labeler.
Non Proprietary Name	Aconiticum Acidum Cis- Apis Venenum Purum Aquilegia Vulgaris Bovista Cypripedium Pubescens Estradiol Faecalis (alkaligenes) Folliculinum Funiculus Umbilicalis Suis Glandula Suprarenalis Suis Heart (suis) Hydrastis Canadensis Hypophysis Suis Kreosotum Lachesis Mutus Lilium Tigrinum Magnesia Phosphorica Mercurius Solubilis Mutabile Bacillus (bach) Oophorinum (suis) Petroselinum Sativum Pineal Gland (suis) Placenta Totalis Suis Progesterone Sepia Testosterone Uterus (suis)
	Sometimes called the generic name, this is usually the active ingredient(s) of the product.
Product Type Name	HUMAN OTC DRUG
	Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Labeler Name	Deseret Biologicals, Inc.
	Name of Company corresponding to the labeler code segment of the ProductNDC.
Status	Active
	Possible status values: Active Active NDC Code Deprecated Deprecated NDC Code Unfinished (Unapproved) The following status describes submitted unfinished drugs, including the marketing categories of Active Pharmaceutical Ingredient (API), Drug for Further Processing, Bulk for Human Drug Compounding, and Bulk for Animal Drug Compounding. FDA does not review and approve unfinished products. Therefore, all products having "unfinished" status are considered unapproved.
DEA Schedule	CIII — Schedule III (CIII) Substance
	Schedule III (CIII) Substance The controlled substances in this schedule have an abuse potential and dependence liability less than those in CI and CII, and have an accepted medical use in the United States (US). They include preparations containing limited quantities of certain narcotic drugs, and other nonnarcotic drugs such as: derivatives of barbituric acid, except those that are listed in another schedule, glutethimide (Doriden), methyprylon (Noludar), nalorphine, benzphetamine, chlorphentermine, clortermine, and phendimetrazine. Schedules of Controlled Substances This is the assigned DEA Schedule number as reported by the labeler. Values are CI, CII, CIII, CIV, and CV. The CSA places each controlled substance—drug or other substance—into one of five schedules based on the substance’s medical use, potential for abuse, and safety or dependence liability. The Act also allows substance to be added to or removed from a schedule, and to be rescheduled or transferred from one schedule to another. The basis upon which substances are placed into each of the five schedules is explained below, and examples of drugs’ or other substances within the schedules are listed.

Route & Dosage
Dosage Form Name	LIQUID
	The translation of the DosageForm Code submitted by the firm. The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Route Name	ORAL
	The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Pharmaceutical Classes	ANDROGEN RECEPTOR AGONISTS [MOA], ANDROGEN [EPC], ANDROSTANES [CS], CALCULI DISSOLUTION AGENT [EPC], ESTRADIOL CONGENERS [CS], ESTROGEN RECEPTOR AGONISTS [MOA], ESTROGEN [EPC], INCREASED LARGE INTESTINAL MOTILITY [PE], INHIBITION LARGE INTESTINE FLUID/ELECTROLYTE ABSORPTION [PE], INHIBITION SMALL INTESTINE FLUID/ELECTROLYTE ABSORPTION [PE], MAGNESIUM ION EXCHANGE ACTIVITY [MOA], OSMOTIC ACTIVITY [MOA], OSMOTIC LAXATIVE [EPC], PROGESTERONE [CS], PROGESTERONE [EPC], STIMULATION LARGE INTESTINE FLUID/ELECTROLYTE SECRETION [PE]
	These are the reported pharmaceutical class categories corresponding to the SubstanceNames listed above.

Substance & Strength
Substance Name	ACONITIC ACID, (Z)- - 20 [hp_X]/mL ALCALIGENES FAECALIS - 30 [hp_C]/mL APIS MELLIFERA VENOM (Substance Adverse Reports) - 18 [hp_X]/mL AQUILEGIA VULGARIS (Substance Adverse Reports) - 8 [hp_X]/mL CYPRIPEDIUM PARVIFLORUM VAR. PUBESCENS ROOT (Substance Adverse Reports) - 6 [hp_X]/mL ESCHERICHIA COLI (Substance Adverse Reports) - 30 [hp_C]/mL ESTRADIOL (Substance Adverse Reports) - 30 [hp_X]/mL ESTRONE (Substance Adverse Reports) - 8 [hp_X]/mL GOLDENSEAL (Substance Adverse Reports) - 6 [hp_X]/mL LACHESIS MUTA VENOM (Substance Adverse Reports) - 10 [hp_X]/mL LILIUM LANCIFOLIUM WHOLE FLOWERING (Substance Adverse Reports) - 4 [hp_X]/mL LYCOPERDON UTRIFORME FRUITING BODY (Substance Adverse Reports) - 6 [hp_X]/mL MAGNESIUM PHOSPHATE, DIBASIC TRIHYDRATE (Substance Adverse Reports) - 10 [hp_X]/mL MERCURIUS SOLUBILIS (Substance Adverse Reports) - 10 [hp_X]/mL PETROSELINUM CRISPUM WHOLE (Substance Adverse Reports) - 6 [hp_X]/mL PORK HEART (Substance Adverse Reports) - 8 [hp_X]/mL PROGESTERONE (Substance Adverse Reports) - 30 [hp_X]/mL SEPIA OFFICINALIS JUICE (Substance Adverse Reports) - 10 [hp_X]/mL SUS SCROFA ADRENAL GLAND (Substance Adverse Reports) - 8 [hp_X]/mL SUS SCROFA OVARY (Substance Adverse Reports) - 8 [hp_X]/mL SUS SCROFA PINEAL GLAND (Substance Adverse Reports) - 12 [hp_X]/mL SUS SCROFA PITUITARY GLAND (Substance Adverse Reports) - 13 [hp_X]/mL SUS SCROFA PLACENTA (Substance Adverse Reports) - 6 [hp_C]/mL SUS SCROFA UMBILICAL CORD (Substance Adverse Reports) - 8 [hp_X]/mL SUS SCROFA UTERUS (Substance Adverse Reports) - 8 [hp_X]/mL TESTOSTERONE (Substance Adverse Reports) - 30 [hp_X]/mL WOOD CREOSOTE (Substance Adverse Reports) - 8 [hp_X]/mL
	This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

Drug Package Information
NDC Package Code	43742-2359-1
	The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC.
Package Description	30 ML IN 1 BOTTLE, DROPPER (43742-2359-1)
	A description of the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. For example: 4 BOTTLES in 1 CARTON/100 TABLETS in 1 BOTTLE.
Sample Package	N
	Defines whether given package serves sample purposes.
Package NDC Exclude Flag	N
	This indicates whether the package has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions.
Package Start Marketing Date	20260219
	This is the date that the labeler indicates was the start of its marketing of the drug package.
Package End Marketing Date	N/S (NOT SPECIFIED)
	This is the date the package will no longer be available on the market. If a package is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Packages that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Packages with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.

Product Application & Marketing Information
Product NDC	43742-2359
	The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Application Number	N/S (NOT SPECIFIED)
	This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Marketing Category Name	UNAPPROVED HOMEOPATHIC
	Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Listing Record Certified Through	20271231
	This is the date when the listing record will expire if not updated or certified by the firm.
Product Marketing Start Date	20260219
	This is the date that the labeler indicates was the start of its marketing of the drug product.
Product Marketing End Date	N/S (NOT SPECIFIED)
	This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Product NDC Exclude Flag	N
	This indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions.

Tracking Information
Last Update Date	2026-02-20
	The date that a record was last updated or changed.